Protagonist Therapeutics (PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera. Additionally, Icotrokinra, an orally delivered investigational drug, is in phase 3 clinical trials and is indicated to block biological pathways targeted by marketed injectable antibody drugs. The company is also working on PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist that has completed phase 2 clinical trials in patients with moderate to severe ulcerative colitis. Furthermore, Protagonist Therapeutics develops IL-17 oral peptide antagonist PN-88, an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in the pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.